Equities

Evome Medical Technologies Inc

LNDZF:PKC

Evome Medical Technologies Inc

Actions
  • Price (USD)0.08
  • Today's Change0.00 / 0.00%
  • Shares traded20.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 16:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CAD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.921.937.57
Total Receivables, Net7.806.350
Total Inventory108.10--
Prepaid expenses2.040.220.14
Other current assets, total----5.43
Total current assets211713
Property, plant & equipment, net1311--
Goodwill, net6.4014--
Intangibles, net7.039.38--
Long term investments------
Note receivable - long term00.19--
Other long term assets0.771.01--
Total assets485213
LIABILITIES
Accounts payable6.915.27--
Accrued expenses1.751.37--
Notes payable/short-term debt6.115.160
Current portion long-term debt/capital leases121.04--
Other current liabilities, total11175.43
Total current liabilities38306.47
Total long term debt6.686.560
Total debt25130
Deferred income tax--0--
Minority interest------
Other liabilities, total----0.02
Total liabilities44376.49
SHAREHOLDERS EQUITY
Common stock575531
Additional paid-in capital9.748.073.63
Retained earnings (accumulated deficit)(65)(49)(29)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total2.211.690.94
Total equity4.00156.64
Total liabilities & shareholders' equity485213
Total common shares outstanding847634
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.